Lisinopril Cost in Connecticut 2026

What Does Lisinopril Actually Cost in Connecticut in 2026?

Generic lisinopril averages about $8 per month at Connecticut retail pharmacies when paying cash in 2026. The manufacturer list price sits near $50 per month for certain branded generics, but virtually no patient without insurance pays that figure because discount programs and competition among generic manufacturers have pushed street-level prices down sharply. A 30-tablet supply of 10 mg lisinopril at large chains such as CVS, Walgreens, and Stop and Shop typically rings up between $6 and $12 depending on the specific pharmacy location and the generic manufacturer in stock.

The ACE inhibitor class, which includes lisinopril, is among the most-prescribed antihypertensive drug classes in the United States [1]. Because patent exclusivity expired decades ago, intense generic competition keeps acquisition costs low. The ALLHAT trial (N=33,357), published in JAMA in 2002, confirmed that chlorthalidone, amlodipine, and lisinopril produced similar rates of fatal coronary heart disease or nonfatal MI, making lisinopril a guideline-recommended first-line option without premium pricing [2]. Price transparency is therefore meaningful: a medication that carries Class I evidence and costs $8 per month is accessible to most patients.

Dose affects price only minimally in Connecticut. Moving from 10 mg to 40 mg rarely changes the out-of-pocket cost by more than $2 to $3 per month at cash-pay pharmacies, because all tablets fall within the same generic tier at most distributors [3]. Splitting a higher-dose tablet is sometimes used to reduce costs further, though that requires explicit physician approval given that lisinopril tablets are not scored uniformly across all manufacturers.

The table below maps approximate 2026 cash prices across common doses at Connecticut retail pharmacies:

| Dose | 30-day supply (cash) | 90-day supply (cash) | |------|---------------------|---------------------| | 2.5 mg | $5, $8 | $12, $20 | | 5 mg | $6, $9 | $14, $22 | | 10 mg | $7, $11 | $16, $25 | | 20 mg | $7, $12 | $17, $28 | | 40 mg | $8, $13 | $18, $30 |

These figures represent cash-pay transactions without any discount card. Applying a GoodRx or RxSaver coupon at participating Connecticut pharmacies can drop the 10 mg 30-day cost to as low as $4 at certain locations [4].

Connecticut Medicaid Coverage for Lisinopril

Connecticut Medicaid (HUSKY Health) covers lisinopril, but the benefit comes with a prior authorization requirement. Prescribers must document a qualifying diagnosis, most commonly hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction left ventricular dysfunction, or diabetic nephropathy [5]. Once PA is approved, enrolled members typically pay $0 to $3 per 30-day supply under the HUSKY A and HUSKY D tiers.

The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) and the American College of Cardiology/American Heart Association 2017 guideline both identify ACE inhibitors as preferred agents in patients with chronic kidney disease and diabetes [6]. Connecticut Medicaid's formulary design reflects those recommendations by covering lisinopril at a low cost-share once clinical criteria are met.

Prior authorization for lisinopril through HUSKY Health generally requires: a documented blood pressure reading above 130/80 mmHg on at least two separate clinic visits per the ACC/AHA 2017 threshold [7], or a confirmed diagnosis of HFrEF with ejection fraction below 40%, or a diagnosis of diabetic nephropathy with documented proteinuria [8]. Approvals are typically valid for 12 months and renewable. Prescribers should submit clinical notes and lab values (BMP for potassium and creatinine) with the PA request because HUSKY reviewers commonly request those before approval.

Patients who lose Medicaid coverage mid-year can request a bridge supply at the pharmacy under Connecticut's continuity-of-care rules, which allow up to a 30-day emergency supply at the Medicaid cost-share rate while a new coverage determination is pending [9].

Commercial Insurance and Lisinopril Tiers in Connecticut

Most commercial plans sold through Access Health CT place generic lisinopril on Tier 1 or Tier 2, meaning the copay is $0 to $15 per 30-day fill depending on the plan design. Anthem BlueCross BlueShield of Connecticut, ConnectiCare, and Aetna all list generic ACE inhibitors in the lowest formulary tier for their 2026 small-group and individual plans [10].

High-deductible health plans (HDHPs) are the exception. Before a member meets the deductible, lisinopril is billed at the plan's negotiated rate, which typically runs $6 to $14 for a 30-day generic supply at in-network pharmacies. After the deductible is satisfied, the drug usually drops to $0 to $5 per fill.

Employer-sponsored plans self-insured under ERISA may differ from state-regulated plans because ERISA preempts Connecticut insurance mandates. Employees covered by a self-insured employer should check their Summary Plan Description rather than assuming state formulary rules apply [11]. Prescription benefit managers such as CVS Caremark, Express Scripts, and OptumRx each negotiate separate generic reimbursement schedules, so the actual patient cost can vary even within the same employer benefit year.

Mail-order pharmacy programs frequently offer a 90-day supply for the price of a 60-day copay. For a Tier 1 drug like lisinopril, that structure can reduce the annual out-of-pocket cost from roughly $120 to $80 per year for commercially insured Connecticut patients [12].

Legal Status of Compounded Lisinopril in Connecticut

Compounded lisinopril is legal in Connecticut when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription for a specific patient. The FDA does not consider commercially available generic lisinopril tablets to be in shortage, so a 503A pharmacy may only compound it when there is a documented clinical rationale, such as the need for a liquid formulation for a patient who cannot swallow tablets or a dose not commercially available (for example, 7.5 mg for a pediatric patient) [13].

Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, sets the federal framework. Connecticut state law, enforced by the Connecticut Department of Consumer Protection Drug Control Division, requires compounding pharmacies to hold an active pharmacy permit and comply with USP Chapter 795 standards for non-sterile preparations [14]. Violating those standards exposes pharmacies to license suspension.

Cost at a 503A compounding pharmacy varies. Some compounding pharmacies include lisinopril as part of a broader cardiovascular or metabolic panel and charge a dispensing fee rather than an ingredient cost, because raw lisinopril powder is inexpensive. Patients in Connecticut who require a liquid suspension of lisinopril, commonly needed in pediatric hypertension or in adults with dysphagia, may pay $10 to $30 per month for the compounded product depending on the pharmacy's dispensing fee structure [15].

503B outsourcing facilities (hospital-grade bulk compounders) cannot dispense directly to individual Connecticut patients without a patient-specific prescription, and lisinopril is not on the FDA's current 503B shortage list, so hospital bulk compounding of lisinopril for outpatient use is generally not permitted under federal law [16].

Telehealth Prescribing of Lisinopril in Connecticut

Connecticut law permits telehealth prescribing of lisinopril. Under Connecticut General Statutes Section 19a-906, licensed Connecticut prescribers may establish a patient-provider relationship via real-time audio-video consultation and issue a prescription for a non-controlled substance such as lisinopril without an in-person visit [17]. The prescription must comply with all standard requirements, including a valid DEA number if applicable, though lisinopril is not a controlled substance.

Telehealth platforms operating in Connecticut, including HealthRX, typically use an initial synchronous video visit to review blood pressure readings the patient submits via a home monitor, assess kidney function through recent labs, and confirm no contraindications such as prior angioedema with an ACE inhibitor or confirmed bilateral renal artery stenosis [18]. The FDA-approved prescribing information for lisinopril warns that patients with a history of ACE-inhibitor-related angioedema should not receive the drug regardless of channel of care [19].

Home blood pressure monitoring accuracy matters here. The American Heart Association recommends using a validated upper-arm cuff device, measuring twice in the morning and twice in the evening for seven consecutive days, then averaging the readings to establish a baseline [20]. Telehealth prescribers in Connecticut who follow that protocol before initiating lisinopril are aligned with AHA and ACC guidance.

Follow-up lab work (basic metabolic panel to check potassium and creatinine) is typically ordered at two to four weeks after initiation or dose change, consistent with JNC 8 guidance on ACE inhibitor monitoring [21]. Connecticut telehealth platforms with affiliated lab networks can route that order to a LabCorp or Quest draw site near the patient, keeping the entire care loop outside a traditional clinic visit.

Connecticut Lisinopril Discount Programs and Savings Cards

Several cost-reduction programs layer on top of cash-pay prices in Connecticut.

GoodRx. Free to join, accepted at most major chains in Connecticut. The GoodRx price for lisinopril 10 mg (30 tablets) at Connecticut pharmacies ranges from roughly $4 to $9 depending on location. GoodRx coupons cannot be used simultaneously with insurance, including Medicaid [22].

NeedyMeds. A nonprofit database of patient assistance programs. NeedyMeds lists manufacturer and state programs specifically for Connecticut residents who meet income thresholds [23]. For lisinopril, because it is a high-volume generic, patient assistance programs are less common than for branded drugs, but the database is worth checking for any patient below 200% of the federal poverty level.

Connecticut Pharmaceutical Assistance Contract to the Elderly (PACE) and PACE Expanded. Connecticut's state-run program for residents aged 65 and older (PACE) and those aged 18 to 64 with certain disabilities (PACE Expanded) covers prescription drugs including lisinopril at reduced cost-sharing. Income limits and enrollment requirements apply, and the Connecticut Department of Social Services administers the program [24].

Manufacturer programs. Generic lisinopril is produced by multiple manufacturers including Lupin, Zydus, and Aurobindo. None currently maintain branded patient assistance programs for their generic versions because the cash price is already low enough that regulatory justification for a program does not exist. If a prescriber writes specifically for a branded generic or a specific manufacturer, the patient may inadvertently pay more.

340B-covered facilities. Connecticut federally qualified health centers (FQHCs) and certain hospital outpatient departments participating in the 340B Drug Pricing Program can dispense lisinopril to eligible patients at 340B acquisition cost, which may be lower than the already-low generic cash price [25]. Patients receiving care at Community Health Center, Inc., Fair Haven Community Health Care, or other Connecticut FQHCs may access this pricing automatically if their provider is 340B-covered.

Lisinopril Pharmacology and Why Pricing Matters for Adherence

Lisinopril is an ACE inhibitor that competitively inhibits angiotensin-converting enzyme, reducing the conversion of angiotensin I to angiotensin II. Lower angiotensin II means reduced vasoconstriction, decreased aldosterone secretion, lower sodium retention, and net antihypertensive effect [26]. The drug is excreted renally, so dose adjustment is required for estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2.

Cost directly affects adherence. A 2018 study published in the Journal of the American Medical Association (JAMA) found that medication out-of-pocket costs above $10 per month were independently associated with a 12% to 19% reduction in adherence to antihypertensive therapy [27]. Given that uncontrolled hypertension accounts for approximately 50% of cardiovascular disease burden [28], the difference between a $4 GoodRx lisinopril fill and a $30 uninsured fill is clinically meaningful.

The ALLHAT trial directly compared lisinopril against chlorthalidone and amlodipine over a mean 4.9-year follow-up in 33,357 high-risk hypertensive adults [2]. Lisinopril was non-inferior for the primary endpoint of fatal coronary heart disease or nonfatal MI (relative risk 0.99, P = 0.81), providing the evidence base for its continued guideline endorsement [2]. Cost barriers that push patients to discontinue an evidence-backed drug with a P<0.001 mortality signal in heart failure subgroups represent a preventable clinical problem.

For patients with HFrEF, the CONSENSUS trial (N=253) demonstrated that enalapril, a closely related ACE inhibitor, reduced all-cause mortality by 40% at six months compared with placebo [29]. The ACC/AHA 2022 heart failure guideline gives ACE inhibitors a Class I, Level of Evidence A recommendation for HFrEF [30]. Lisinopril carries the same mechanistic benefit and the same FDA indication; at $8 per month, barriers to access are low but not zero for uninsured Connecticut patients.

Monitoring Requirements That Affect Total Cost of Care

Lisinopril requires periodic laboratory monitoring that adds to total treatment cost even when the drug itself is inexpensive. The standard monitoring schedule per ACC/AHA guidance is [31]:

• Baseline: basic metabolic panel (BMP) including serum potassium, creatinine, and eGFR before initiation
• Two to four weeks after initiation or dose change: repeat BMP
• Ongoing: BMP every six to twelve months in stable patients with no CKD
• CKD patients (eGFR <60 mL/min/1.73 m2): BMP every three months

A BMP through a Connecticut commercial lab (LabCorp or Quest) costs roughly $15 to $35 without insurance. Connecticut Medicaid covers lab work at $0 patient cost-share for enrolled members. Factoring in biannual BMP testing, the total annualized cost of lisinopril therapy for an uninsured Connecticut patient is approximately $96 to $156 per year for the drug plus $30 to $70 for labs, totaling $126 to $226 per year [32]. That figure remains well below many branded antihypertensive regimens.

Patients should also be counseled that potassium-sparing diuretics (spironolactone, amiloride), potassium supplements, and NSAIDs each alter the risk-benefit calculation of lisinopril. The FDA-approved prescribing label identifies dual ACE/ARB blockade as contraindicated in diabetic patients due to increased renal impairment risk, consistent with the ONTARGET trial findings [33].

How Connecticut Compares to Neighboring States

Connecticut's cash-pay price of roughly $8 per month for generic lisinopril sits in line with the national average for retail generics [34]. Massachusetts reports a similar $7 to $9 range. New York's price is comparable at $6 to $11, with variation driven by the density of discount pharmacies in New York City versus rural counties. Rhode Island pharmacies average $7 to $10.

Connecticut does not have a state-specific price control on generic pharmaceuticals beyond the Medicaid supplemental rebate system. The Connecticut Prescription Drug Monitoring Program (PDMP) tracks controlled substance prescriptions but does not govern lisinopril, which is a non-controlled drug [35]. State-level policy efforts such as SB 987 (2023 session) proposed a $50 monthly cap on certain chronic-disease medications, though that legislation did not advance to include generic ACE inhibitors given their already-low market price [36].

For uninsured patients who recently moved to Connecticut from a state with higher pharmacy prices, the transition may actually reduce out-of-pocket costs due to Connecticut's concentration of large chain pharmacies that participate in aggressive GoodRx network pricing.

When to Contact a Connecticut Prescriber About Lisinopril

Stop taking lisinopril and contact a physician or go to an emergency department immediately if you experience swelling of the face, lips, tongue, or throat, which are signs of angioedema. The FDA reports an angioedema incidence of roughly 0.1% to 0.2% with ACE inhibitors, and Black patients face a three- to four-times higher relative risk compared with white patients [37]. That differential has direct implications for prescriber counseling in Connecticut, which has significant Black and African American communities in Hartford, Bridgeport, and New Haven.

A persistent dry cough occurs in 5% to 20% of ACE inhibitor users and is a common reason for switching to an angiotensin receptor blocker (ARB) such as losartan [38]. ARBs carry similar evidence for hypertension and HFrEF but may cost more out of pocket depending on formulary tier. Prescribers in Connecticut should document cough clearly so that a subsequent ARB prescription does not face unnecessary PA delays with Connecticut Medicaid.